ERBB2 and gastric cancer: Trastuzumab–deruxtecan (T-Dxd) is a new ADC, composed of an anti-HER2 antibody and a topoisomerase I inhibitor payload, that has significantly improved the prognosis of HER2-positive breast and gastric cancer [72,73].